What question did this study set out to answer?

The aim is to explore the effectiveness of chimeric antigen receptor T-cell therapy for treating hematological malignancies.

December 15, 2014Immunological Reviews

Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies

View Full Paper

Ask AI

Bookmark

The aim is to explore the effectiveness of chimeric antigen receptor T-cell therapy for treating hematological malignancies.
Review of over 100 clinical trials and their outcomes involving anti-CD19 redirected T cells.
Analysis of active clinical trials targeting CD19 across North America, Europe, and Asia.
Examination of ongoing studies targeting non-CD19 hematological and solid malignancies.
CD19-targeted therapy shows significant potential in treating high-risk B-cell malignancies.
More than 30 active clinical trials are currently recruiting patients for CD19 therapies.
Emerging data indicate a favorable safety and efficacy profile for chimeric antigen receptor T-cell therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial investigates chimeric antigen receptor T-cell therapy in patients with hematological malignancies, suggesting promising results for immunotherapy.

Cite This Study

Gill et al. (2014) studied this question.

synapsesocial.com/papers/6a0890f41e8b9db648de17a2 https://doi.org/10.1111/imr.12243

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial investigates chimeric antigen receptor T-cell therapy in patients with hematological malignancies, suggesting promising results for immunotherapy.

Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies

Key Points

Discussion

Implication

Cite This Study

Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider